Cholangiocarcinoma: Molecular Drivers, Microenvironment, and Precision Medicine, Organized by Alphonse E. Sirica, Virginia Commonwealth University
Cholangiocarcinoma (CCA) is a heterogeneous class of highly aggressive and fatal primary epithelial cancers arising within the biliary tract. After hepatocellular carcinoma, CCA is the second most common primary liver cancer, accounting for approximately 10-20% of all primary hepatic malignancies. Over the last 10-20 years, intrahepatic CCA has notably become the focus of increasing concern largely due to its rising incidence and high mortality rates in various parts of the world. In the USA, the rising incidence and mortality rates from this primary hepatobiliary cancer, particularly over the past decade or so, has coincided with a rapidly growing interest among clinicians, investigators, and patient advocates seeking greater mechanistic insights and more personalized targeted molecular and immunotherapeutic approaches for managing and/or preventing this challenging hepatobiliary cancer. We will highlight timely research findings focused on key molecular drivers, the tumor reactive stroma, and immune milieu in relation to CCA development, malignant progression, morpho-molecular heterogeneity, and therapeutic resistance, together with emerging strategies for advancing novel molecular and immunotherapies for CCA.